First human trial launched for deadly virus vaccine
NCT ID NCT06684431
Summary
This early-stage study tested the safety of a new DNA vaccine designed to protect against Crimean-Congo hemorrhagic fever, a serious viral disease. Fifteen healthy volunteers received three doses of the experimental vaccine over several weeks. Researchers monitored participants for side effects and measured their immune responses to see if the vaccine triggered protective antibodies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRIMEAN CONGO HEMORRHAGIC FEVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Phase I Unit, Karolinska University Hospital
Stockholm, Stockholm County, 17176, Sweden
Conditions
Explore the condition pages connected to this study.